Is intraductal papillary mucinous neoplasm (IPMN) likely to cause pain?

Is IPMN Likely to Cause Pain?

Pain is a relatively common symptom in IPMN patients but has low predictive value for malignancy, occurring in approximately 59-75% of patients at presentation, though the evidence linking pain specifically to malignant transformation is weak. 1

Clinical Context of Pain in IPMN

Pain manifests as abdominal discomfort, epigastric pain, or backache in the majority of symptomatic IPMN patients. In surgical series, 75% of patients experienced epigastric discomfort and/or pain as well as backache 2, and another large series reported abdominal pain as the most common presenting symptom in 59% of patients 3.

Important Distinction: Pain as a Symptom vs. Risk Factor

The European evidence-based guidelines explicitly state that "the presence of new-onset diabetes, pancreatitis, and abdominal pain have been associated with malignancy at varying rates, indicating that the level of evidence for these risk factors is low" 1. This means:

• Pain occurs frequently in IPMN patients overall
• Pain alone does NOT reliably predict which IPMNs harbor high-grade dysplasia or invasive carcinoma
• Pain should NOT be used as a primary criterion for surgical decision-making

When Pain Becomes Clinically Significant

Pain in IPMN patients warrants further investigation when accompanied by:

• High-risk stigmata: jaundice, enhancing mural nodule ≥5 mm, main pancreatic duct (MPD) ≥10 mm, or positive cytology 1
• Worrisome features: MPD 5-9.9 mm, cyst ≥40 mm, rapid growth ≥5 mm/year, elevated CA 19-9 >37 U/mL, or enhancing mural nodules <5 mm 1
• Acute pancreatitis: 58% of patients in one series had a history of acute pancreatitis 2

Clinical Pitfalls to Avoid

1. Do not dismiss pain entirely: While pain has low specificity for malignancy, it may indicate complications like pancreatitis or, rarely, pseudoaneurysm rupture 4

2. Do not use pain alone as an indication for surgery: The guidelines emphasize that symptoms (including pain) are associated with malignancy "at varying rates" but lack strong predictive value 1

3. Investigate the underlying cause: Pain may result from:

   • Associated acute or chronic pancreatitis
   • Pancreatic duct obstruction
   • Rapid cyst expansion
   • Concurrent pancreatic ductal adenocarcinoma (occurs in ~7% of IPMN patients) 5

Practical Management Algorithm

When an IPMN patient presents with pain:

1. Assess for high-risk stigmata and worrisome features using MRI (preferred) or EUS 1
2. Check serum CA 19-9 and amylase/lipase to evaluate for malignancy markers and pancreatitis
3. Evaluate for complications including pancreatitis or vascular complications
4. Base surgical decisions on imaging findings and risk stratification, not on pain alone
5. Consider that pain may indicate concomitant pancreatic ductal adenocarcinoma separate from the IPMN itself 5

The presence of pain should prompt thorough evaluation but should not independently drive surgical decision-making in the absence of established high-risk features.